


**Product Name** : AVL-292  
**Cat. No.** : PC-45401  
**CAS No.** : 1202757-89-8  
**Molecular Formula** : C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 423.4402  
**Target** : BTK  
**Solubility** : DMSO: ≥ 45 mg/mL



## Biological Activity

AVL-292 (Spebrutinib, CC-292) is a highly selective, covalent **Btk** inhibitor with IC<sub>50</sub> of <1 nM.

AVL-292 (Spebrutinib, CC-292) also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC<sub>50</sub>s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, respectively.

AVL-292 (Spebrutinib, CC-292) shows anti-inflammatory activity in the collagen-induced arthritis model of autoimmune disease.

AVL-292 (Spebrutinib, CC-292) also prevents NRG- and EGF-dependent growth factor-driven resistance to lapatinib in HER2(+) breast cancer cells.

## References

Evans EK, et al. *J Pharmacol Exp Ther.* 2013 Aug;346(2):219-28.

Eda H, et al. *Leukemia.* 2014 Sep;28(9):1892-901.

Wang X, et al. *Mol Cancer Ther.* 2016 Sep;15(9):2198-208.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com